Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice
<p> <b>A.V. Kuroyedov<sup>1,2</sup>, O.V. Gapon’ko<sup>1,2</sup>, V.V. Gorodnichiy<sup>1</sup>, S.V. Diordiychuk<sup>1</sup>, I.V. Kondrakova<sup>1</sup>, N.M. Sol’nov<sup>1</sup>, N.E. Fomin<su...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Prime-Media
2020-11-01
|
| Series: | РМЖ "Клиническая офтальмология" |
| Online Access: | http://clinopht.com/upload/iblock/e0f/e0f0ad6eb54a8f723be23cf395cb0ca8.pdf |
| _version_ | 1797294990893776896 |
|---|---|
| author | A.V. Kuroyedov O.V. Gapon’ko V.V. Gorodnichiy S.V. Diordiychuk I.V. Kondrakova N.M. Sol’nov N.E. Fomin |
| author_facet | A.V. Kuroyedov O.V. Gapon’ko V.V. Gorodnichiy S.V. Diordiychuk I.V. Kondrakova N.M. Sol’nov N.E. Fomin |
| author_sort | A.V. Kuroyedov |
| collection | DOAJ |
| description | <p>
<b>A.V. Kuroyedov<sup>1,2</sup>, O.V. Gapon’ko<sup>1,2</sup>, V.V. Gorodnichiy<sup>1</sup>, S.V. Diordiychuk<sup>1</sup>, I.V. Kondrakova<sup>1</sup>, N.M. Sol’nov<sup>1</sup>, N.E. Fomin<sup>1,2</sup></b>
</p>
<p>
<b><sup>1</sup>P.V. Mandryka Military Clinical Hospital, Moscow, Russian Federation</b>
</p>
<p>
<b><sup>2</sup>Pirogov Russian National Research Medical University, Moscow, Russian Federation</b>
</p>
<p>
<i><b>Aim</b>: to assess the effectiveness and tolerability of anti-VEGF agents, aflibercept (2.0 mg) and ranibizumab (0.5 mg), in the combined treatment for wet age-related macular degeneration (AMD) in routine clinical practice.</i>
</p>
<p>
<i><b>Patients and Methods:</b> 55 patients (65 eyes) with the late stage of wet AMD were divided into two groups. Group 1 included 32 eyes with classic choroidal neovascularization (CNV) and group 2 included 33 eyes with occult CNV. Best-corrected visual acuity (BCVA), intraocular pressure, and retinal nerve fiber layer (RNFL) thickness were measured. These parameters were compared at different time points during the treatment.</i>
</p>
<p>
<i><b>Results</b>: overall AMD duration (January 2019) was 36 (19; 47) months being 30 (12; 44) months in group 1 and 36 (23; 48) months in group 2 (р>0.05). The first intravitreal administration of an anti-VEGF drug was performed 7.5 (3.5; 9.5) months after AMD diagnosis in group 1 and 7 (3; 11) months after AMD diagnosis in group 2. Significant differences in intragroup intervals were revealed between various follow-up periods. More differences were identified for the intervals between intravitreal administrations in group 2. Baseline and final BCVA during the entire follow-up which was 29.5 (19.5; 38) months in group 1 and 28 (25; 44) months in group 2 demonstrated neither intragroup nor intergroup differences (р>0.05).</i>
</p>
<p>
<i><b>Conclusion</b>: our management strategy for wet AMD is somewhat different from conventional guidelines. However, it has no significant impact on visual acuity during the follow-up.</i>
</p>
<p>
<i><b>Keywords</b>: age-related macular degeneration, anti-VEGF drugs, intravitreal administration, IOP level, aflibercept, ranibizumab.</i>
</p>
<p>
<i><b>For citation: </b>Kuroyedov A.V., Gapon’ko O.V., Gorodnichiy V.V. et al. Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice. Russian Journal of Clinical Ophthalmology. 2020;20(4):209–215. DOI: 10.32364/2311-7729-2020-20-4-209-215.</i>
</p>
<i><br>
</i><br> |
| first_indexed | 2024-03-07T21:39:10Z |
| format | Article |
| id | doaj.art-182e2aa8db734cd88a0cb475bccc25ce |
| institution | Directory Open Access Journal |
| issn | 2311-7729 2619-1571 |
| language | Russian |
| last_indexed | 2024-03-07T21:39:10Z |
| publishDate | 2020-11-01 |
| publisher | Prime-Media |
| record_format | Article |
| series | РМЖ "Клиническая офтальмология" |
| spelling | doaj.art-182e2aa8db734cd88a0cb475bccc25ce2024-02-26T10:12:11ZrusPrime-MediaРМЖ "Клиническая офтальмология"2311-77292619-15712020-11-0120431221Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practiceA.V. Kuroyedov0O.V. Gapon’ko1V.V. Gorodnichiy2S.V. Diordiychuk3I.V. Kondrakova4N.M. Sol’nov5N.E. Fomin6Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399<p> <b>A.V. Kuroyedov<sup>1,2</sup>, O.V. Gapon’ko<sup>1,2</sup>, V.V. Gorodnichiy<sup>1</sup>, S.V. Diordiychuk<sup>1</sup>, I.V. Kondrakova<sup>1</sup>, N.M. Sol’nov<sup>1</sup>, N.E. Fomin<sup>1,2</sup></b> </p> <p> <b><sup>1</sup>P.V. Mandryka Military Clinical Hospital, Moscow, Russian Federation</b> </p> <p> <b><sup>2</sup>Pirogov Russian National Research Medical University, Moscow, Russian Federation</b> </p> <p> <i><b>Aim</b>: to assess the effectiveness and tolerability of anti-VEGF agents, aflibercept (2.0 mg) and ranibizumab (0.5 mg), in the combined treatment for wet age-related macular degeneration (AMD) in routine clinical practice.</i> </p> <p> <i><b>Patients and Methods:</b> 55 patients (65 eyes) with the late stage of wet AMD were divided into two groups. Group 1 included 32 eyes with classic choroidal neovascularization (CNV) and group 2 included 33 eyes with occult CNV. Best-corrected visual acuity (BCVA), intraocular pressure, and retinal nerve fiber layer (RNFL) thickness were measured. These parameters were compared at different time points during the treatment.</i> </p> <p> <i><b>Results</b>: overall AMD duration (January 2019) was 36 (19; 47) months being 30 (12; 44) months in group 1 and 36 (23; 48) months in group 2 (р>0.05). The first intravitreal administration of an anti-VEGF drug was performed 7.5 (3.5; 9.5) months after AMD diagnosis in group 1 and 7 (3; 11) months after AMD diagnosis in group 2. Significant differences in intragroup intervals were revealed between various follow-up periods. More differences were identified for the intervals between intravitreal administrations in group 2. Baseline and final BCVA during the entire follow-up which was 29.5 (19.5; 38) months in group 1 and 28 (25; 44) months in group 2 demonstrated neither intragroup nor intergroup differences (р>0.05).</i> </p> <p> <i><b>Conclusion</b>: our management strategy for wet AMD is somewhat different from conventional guidelines. However, it has no significant impact on visual acuity during the follow-up.</i> </p> <p> <i><b>Keywords</b>: age-related macular degeneration, anti-VEGF drugs, intravitreal administration, IOP level, aflibercept, ranibizumab.</i> </p> <p> <i><b>For citation: </b>Kuroyedov A.V., Gapon’ko O.V., Gorodnichiy V.V. et al. Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice. Russian Journal of Clinical Ophthalmology. 2020;20(4):209–215. DOI: 10.32364/2311-7729-2020-20-4-209-215.</i> </p> <i><br> </i><br>http://clinopht.com/upload/iblock/e0f/e0f0ad6eb54a8f723be23cf395cb0ca8.pdf |
| spellingShingle | A.V. Kuroyedov O.V. Gapon’ko V.V. Gorodnichiy S.V. Diordiychuk I.V. Kondrakova N.M. Sol’nov N.E. Fomin Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice РМЖ "Клиническая офтальмология" |
| title | Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice |
| title_full | Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice |
| title_fullStr | Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice |
| title_full_unstemmed | Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice |
| title_short | Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice |
| title_sort | effectiveness and tolerability of the combined use of anti vegf agents in clinical practice |
| url | http://clinopht.com/upload/iblock/e0f/e0f0ad6eb54a8f723be23cf395cb0ca8.pdf |
| work_keys_str_mv | AT avkuroyedov effectivenessandtolerabilityofthecombineduseofantivegfagentsinclinicalpractice AT ovgaponko effectivenessandtolerabilityofthecombineduseofantivegfagentsinclinicalpractice AT vvgorodnichiy effectivenessandtolerabilityofthecombineduseofantivegfagentsinclinicalpractice AT svdiordiychuk effectivenessandtolerabilityofthecombineduseofantivegfagentsinclinicalpractice AT ivkondrakova effectivenessandtolerabilityofthecombineduseofantivegfagentsinclinicalpractice AT nmsolnov effectivenessandtolerabilityofthecombineduseofantivegfagentsinclinicalpractice AT nefomin effectivenessandtolerabilityofthecombineduseofantivegfagentsinclinicalpractice |